# Autifony Therapeutics: Research, Stevenage, United Kingdom

> Autifony Therapeutics: Autifony Therapeutics is a clinical-stage biotechnology company founded in 2011 as a spinout from GSK.

Source: https://millionrounds.com/startup/autifony-therapeutics (Millionrounds; every figure on the page links to its filing or article)

United Kingdom · [Research startup](https://millionrounds.com/companies)

# Autifony Therapeutics

Autifony Therapeutics is a clinical-stage biotechnology company founded in 2011 as a spinout from GSK.

Funding reported Last round: Venture (Round not Specified)

Research Stevenage, United Kingdom

Company summary

- **Founded:** 2011 15 years old
- **Team:** 30 11 to 50 people
- **Funding reported:** 28.8M as listed, currency not stated
- **Last round:** Venture (Round not Specified) Mar 2017

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Autifony Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Autifony Therapeutics

Autifony Therapeutics is a clinical-stage biotechnology company founded in 2011 as a spinout from GSK.

Based in Stevenage, UK, the company focuses on developing innovative medicines for rare and serious central nervous system (CNS) disorders by targeting the Kv3 family of ion channels. Their research aims to change treatment paradigms for conditions such as Fragile X syndrome, rare epilepsy, schizophrenia, and hearing disorders. The company operates a specialized ion channel drug discovery platform that develops small-molecule modulators to regulate neuronal excitability. Autifony's pipeline includes clinical-stage assets like AUT00206, which targets Fragile X syndrome and has received FDA Orphan Drug Designation, and AUT00063, aimed at tinnitus and age-related hearing loss. Additionally, they have preclinical programs addressing schizophrenia, Alzheimer’s disease, and rare epilepsy syndromes. Autifony collaborates with key investors and partners, including Boehringer Ingelheim and GSK, to advance their therapeutic approaches in the healthcare and biopharmaceutical market.

## What company datasets say Autifony Therapeutics raised

Funding, as reported

Reported in all **28.8M** in the source's currency

Last round **Venture (Round not Specified)**

Last round size **1.7M**

Last round date **Mar 2017**

## Funding filed with regulators

Autifony Therapeutics filed one raise, $784K in all. Filings say how much was sold and to how many investors; they never name the investors.

- Nov 2023 **$784K** UK share allotment

## Founders and team

From Autifony Therapeutics's own website: 2 on the team.

- **Alice Sharman** Head of Clinical Project Management
- **Dean Rivers** Director of Medicinal Chemistry

## The company, in detail

What they build

Known for

health care clinical-stage medicines autifony pipeline biotechnology research ion channel drug discovery clinical trials in cns small molecule drugs hospital & health care medical target validation kv3 potassium channels ion channel science health biotechnology services rare cns disorders

Built with from their website

Google Maps AMP CloudFlare CDN Priority Hints Google Font API WordPress.org Microsoft Exchange Cloudflare Insights Microsoft 365 MySQL

+8 more

PrimeNG Cloudflare DNS Outlook Olo CloudFlare Microsoft 365 Apps & Services PHP Viewport Meta

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834, 8731
- **Region:** England
- **Revenue:** 19.3M a year, as listed

## Research in United Kingdom

Startups like it

- [**Isomorphic Labs** London · founded 2021 *Raised*](https://millionrounds.com/company/isomorphic-labs)
- [**Basecamp Research** London · founded 2019 *Raised*](https://millionrounds.com/company/basecamp-research)
- [**Callosum** London · founded 2025 *Raised*](https://millionrounds.com/company/callosum)
- [**Artios** Babraham · founded 2016 *Raised*](https://millionrounds.com/company/artios)
- [**First Light Fusion** Yarnton · founded 2011 *Raised*](https://millionrounds.com/company/first-light-fusion)
- [**IMU Biosciences** London · founded 2019 *Raised*](https://millionrounds.com/company/imu-biosciences)
- [**Orbital Industries** London · founded 2022 *Raised*](https://millionrounds.com/company/orbital-industries)
- [**Genomics** Oxford · founded 2014 *Raised*](https://millionrounds.com/company/genomics)

## Is this your company?

Add your raise, your deck and your story, and put Autifony Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)